CSGALNACT1
Basic information
Region (hg38): 8:19404161-19758029
Links
Phenotypes
GenCC
Source:
- skeletal dysplasia, mild, with joint laxity and advanced bone age (Moderate), mode of inheritance: AR
- skeletal dysplasia, mild, with joint laxity and advanced bone age (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Skeletal dysplasia, mild, with joint laxity and advanced bone age | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Musculoskeletal | 27599773; 31325655; 31705726 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (6 variants)
- Skeletal dysplasia, mild, with joint laxity and advanced bone age (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CSGALNACT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 61 | 66 | ||||
missense | 117 | 14 | 137 | |||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 4 | 5 | 9 | |||
non coding | 26 | 18 | 45 | |||
Total | 7 | 3 | 121 | 102 | 27 |
Highest pathogenic variant AF is 0.0000460
Variants in CSGALNACT1
This is a list of pathogenic ClinVar variants found in the CSGALNACT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
8-19405492-G-A | Benign (Nov 11, 2018) | |||
8-19405772-C-A | CSGALNACT1-related disorder | Likely benign (Feb 19, 2019) | ||
8-19405784-GTT-G | Uncertain significance (Feb 10, 2022) | |||
8-19405802-TTC-T | Likely benign (Jan 24, 2024) | |||
8-19405805-T-A | Inborn genetic diseases | Uncertain significance (Jan 05, 2024) | ||
8-19405817-C-G | CSGALNACT1-related disorder | Benign/Likely benign (May 01, 2024) | ||
8-19405821-G-T | Uncertain significance (May 12, 2022) | |||
8-19405828-C-G | Uncertain significance (Nov 08, 2022) | |||
8-19405831-T-C | Inborn genetic diseases | Uncertain significance (Jul 12, 2023) | ||
8-19405832-A-G | Inborn genetic diseases | Uncertain significance (Dec 27, 2023) | ||
8-19405853-A-C | Uncertain significance (Jan 29, 2024) | |||
8-19405861-C-A | Inborn genetic diseases | Uncertain significance (Aug 01, 2022) | ||
8-19405861-C-T | Likely benign (Feb 06, 2023) | |||
8-19405866-C-T | Uncertain significance (Jan 05, 2024) | |||
8-19405867-G-A | Likely benign (Sep 26, 2023) | |||
8-19405868-T-C | Inborn genetic diseases | Uncertain significance (May 31, 2022) | ||
8-19405879-G-A | Likely benign (Jan 24, 2024) | |||
8-19405906-C-G | Inborn genetic diseases | Uncertain significance (Feb 05, 2024) | ||
8-19405914-G-T | Uncertain significance (Oct 05, 2022) | |||
8-19405917-C-T | Inborn genetic diseases | Uncertain significance (Aug 01, 2022) | ||
8-19405918-G-A | CSGALNACT1-related disorder | Likely benign (Jun 07, 2023) | ||
8-19405920-G-C | Inborn genetic diseases | Uncertain significance (Mar 02, 2023) | ||
8-19405930-G-A | Benign (Jan 31, 2024) | |||
8-19405931-T-C | Uncertain significance (Nov 08, 2022) | |||
8-19405934-A-T | Uncertain significance (Aug 10, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CSGALNACT1 | protein_coding | protein_coding | ENST00000454498 | 7 | 353869 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
9.27e-14 | 0.0387 | 125687 | 1 | 60 | 125748 | 0.000243 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -2.63 | 425 | 297 | 1.43 | 0.0000184 | 3527 |
Missense in Polyphen | 180 | 136.35 | 1.3202 | 1632 | ||
Synonymous | -4.14 | 173 | 116 | 1.49 | 0.00000739 | 1001 |
Loss of Function | 0.312 | 21 | 22.6 | 0.929 | 0.00000123 | 257 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000243 | 0.000242 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000707 | 0.000707 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.000255 | 0.000255 |
Middle Eastern | 0.000707 | 0.000707 |
South Asian | 0.000359 | 0.000327 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Transfers 1,4-N-acetylgalactosamine (GalNAc) from UDP- GalNAc to the non-reducing end of glucuronic acid (GlcUA). Required for addition of the first GalNAc to the core tetrasaccharide linker and for elongation of chondroitin chains. Important role in chondroitin chain biosynthesis in cartilage formation and subsequent endochondral ossification (PubMed:11788602, PubMed:12163485, PubMed:12446672, PubMed:17145758). Moreover, is involved in the metabolism of aggrecan (By similarity). {ECO:0000250|UniProtKB:Q8BJQ9, ECO:0000269|PubMed:11788602, ECO:0000269|PubMed:12163485, ECO:0000269|PubMed:12446672, ECO:0000269|PubMed:17145758, ECO:0000269|PubMed:21160489, ECO:0000269|PubMed:27599773}.;
- Pathway
- Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate - Homo sapiens (human);Metabolism of carbohydrates;Chondroitin sulfate biosynthesis;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;chondroitin sulfate biosynthesis (late stages);Proteoglycan biosynthesis;chondroitin sulfate biosynthesis;dermatan sulfate biosynthesis;Metabolism;chondroitin and dermatan biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.115
Intolerance Scores
- loftool
- 0.799
- rvis_EVS
- -0.1
- rvis_percentile_EVS
- 45.65
Haploinsufficiency Scores
- pHI
- 0.497
- hipred
- N
- hipred_score
- 0.441
- ghis
- 0.482
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.425
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Csgalnact1
- Phenotype
- limbs/digits/tail phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- endochondral ossification;nervous system development;cell recognition;cell population proliferation;anatomical structure morphogenesis;heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;UDP-N-acetylgalactosamine metabolic process;proteoglycan biosynthetic process;extracellular matrix organization;chondroitin sulfate biosynthetic process;heparin biosynthetic process;UDP-glucuronate metabolic process;chondroitin sulfate proteoglycan biosynthetic process;dermatan sulfate proteoglycan biosynthetic process;chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;cartilage development
- Cellular component
- Golgi membrane;integral component of Golgi membrane;Golgi cisterna membrane
- Molecular function
- acetylgalactosaminyltransferase activity;peptidoglycan glycosyltransferase activity;glucuronosyltransferase activity;metal ion binding;glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase activity;glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity